Phenotypes associated with this allele

• Allele Symbol: Gt(ROSA)26Sor^{tm3(CAG-MIR17-92,-EGFP)Rsky}
• Allele Name: targeted mutation 3, Klaus Rajewsky
• Allele ID: MGI:3778920
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gt(ROSA)26Sor^tm3(CAG-MIR17-92,-EGFP)Rsky/Gt(ROSA)26Sor^+ Tg(CD2-icre)4Kio/0	involves: C57BL/6 * C57BL/10 * CBA/Ca	MGI:3783574
cn2	Gt(ROSA)26Sor^tm3(CAG-MIR17-92,-EGFP)Rsky/Gt(ROSA)26Sor^tm3(CAG-MIR17-92,-EGFP)Rsky Tg(CD2-icre)4Kio/0	involves: C57BL/6 * C57BL/10 * CBA/Ca	MGI:3783575

Genotype
MGI:3783574

cn1

• Allelic Composition: Gt(ROSA)26Sor^{tm3(CAG-MIR17-92,-EGFP)Rsky}/Gt(ROSA)26Sor⁺; Tg(CD2-icre)4Kio/0
• Genetic Background: involves: C57BL/6 * C57BL/10 * CBA/Ca

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

decreased marginal zone B cell number ( J:133215 )

increased B-1a cell number ( J:133215 )

• mice exhibit more CD19+B220^loCD5+CD43+CD23- B-1a cells in the spleen and peritoneal cavity compared to in wild-type mice

hematopoietic system

decreased marginal zone B cell number ( J:133215 )

increased B-1a cell number ( J:133215 )

• mice exhibit more CD19+B220^loCD5+CD43+CD23- B-1a cells in the spleen and peritoneal cavity compared to in wild-type mice

Genotype
MGI:3783575

cn2

• Allelic Composition: Gt(ROSA)26Sor^{tm3(CAG-MIR17-92,-EGFP)Rsky}/Gt(ROSA)26Sor^{tm3(CAG-MIR17-92,-EGFP)Rsky}; Tg(CD2-icre)4Kio/0
• Genetic Background: involves: C57BL/6 * C57BL/10 * CBA/Ca

mortality/aging

premature death ( J:133215 )

• all mice die by 55 weeks of age

immune system

immune system phenotype ( J:133215 )

N • despite increased immunoglobulin, cytokine levels in the blood are normal

abnormal immune system morphology ( J:133215 )

increased spleen weight ( J:133215 )

• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice

spleen hyperplasia ( J:133215 )

• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice

abnormal T cell differentiation ( J:133215 )

• prior to 14 weeks of age, mice exhibit a 2-fold higher percentage of thymocytes at the double negative stage compared to in wild-type mice

• however, the total number of thymocytes is unchanged

increased lymphocyte cell number ( J:133215 )

• at 5 weeks of age

increased B cell number ( J:133215 )

increased germinal center B cell number ( J:133215 )

• in the spleen and peripheral lymph nodes

increased B-1a cell number ( J:133215 )

• mice exhibit more CD19+B220^loCD5+CD43+CD23- B-1a cells in the spleen and peritoneal cavity compared to in wild-type mice

increased CD8-positive, alpha-beta T cell number ( J:133215 )

abnormal B cell morphology ( J:133215 )

• spleen and lymph node B cells exhibit increased cell size compared to in wild-type mice

abnormal CD4-positive, alpha beta T cell morphology ( J:133215 )

• CD4+ T cells exhibit increased proliferation and survival following stimulation with CD3 alone unlike wild-type cells

increased CD4-positive, alpha-beta T cell number ( J:133215 )

decreased spleen red pulp amount ( J:133215 )

intermingled spleen red and white pulp ( J:133215 )

abnormal spleen marginal zone morphology ( J:133215 )

• the spleen marginal zone is disrupted unlike in wild-type mice

decreased marginal zone B cell number ( J:133215 )

increased spleen white pulp amount ( J:133215 )

enlarged lymph nodes ( J:133215 )

• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice

lymph node hyperplasia ( J:133215 )

• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice

abnormal immune system physiology ( J:133215 )

• mice exhibit massive infiltration of lymphocytes into the salivary glands and lungs with some infiltration of the kidneys unlike in wild-type mice

abnormal B cell activation ( J:133215 )

• B cells are more resistance than in wild-type mice to Fas-mediated cell death following activation

• activated B cells exhibit enhanced proliferation and survival compared to wild-type cells

increased B cell proliferation ( J:133215 )

• B-2 cell proliferation is enhanced following activation with anti-IgM or lipopolysaccharides unlike in wild-type cells

abnormal immunoglobulin level ( J:133215 )

increased IgG2a level ( J:133215 )

• 4- to 6-fold at 8 to 12 weeks of age

increased IgG2b level ( J:133215 )

• 4- to 6-fold at 8 to 12 weeks of age

increased IgG3 level ( J:133215 )

• 4- to 6-fold at 8 to 12 weeks of age

increased IgM level ( J:133215 )

• 4- to 6-fold at 8 to 12 weeks of age

abnormal CD4-positive, alpha-beta T cell physiology ( J:133215 )

• more CD4+ T cells produce IFN-gamma and IL-10 but not IL-4 or TNF than wild-type cells

• CD4+T cells from older mice produce more IFN-gamma and IL-10 than CD4+ T cells from younger mice

abnormal T cell activation ( J:133215 )

• activated T cells exhibit enhanced proliferation and survival compared to wild-type cells

increased anti-double stranded DNA antibody level ( J:133215 )

• at 18 to 25 weeks

increased anti-single stranded DNA antibody level ( J:133215 )

• at 18 to 25 weeks

renal/urinary system

increased urine protein level ( J:133215 )

• in some mice

abnormal glomerular mesangium morphology ( J:133215 )

• a subset of mice show marked accumulation of IgG and the C3d component of complement in the mesangium and segmentally in the periphery of glomeruli

increased mesangial cell number ( J:133215 )

expanded mesangial matrix ( J:133215 )

• mice exhibit mesangial expansion unlike in wild-type mice

renal glomerulus hypertrophy ( J:133215 )

• mice exhibit enlarged renal glomeruli with hypercellularity and mesangial expansion unlike in wild-type mice

pale kidney ( J:133215 )

• in some mice

homeostasis/metabolism

increased urine protein level ( J:133215 )

• in some mice

hematopoietic system

increased spleen weight ( J:133215 )

• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice

spleen hyperplasia ( J:133215 )

• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice

abnormal T cell differentiation ( J:133215 )

• prior to 14 weeks of age, mice exhibit a 2-fold higher percentage of thymocytes at the double negative stage compared to in wild-type mice

• however, the total number of thymocytes is unchanged

extramedullary hematopoiesis ( J:133215 )

increased lymphocyte cell number ( J:133215 )

• at 5 weeks of age

increased B cell number ( J:133215 )

increased germinal center B cell number ( J:133215 )

• in the spleen and peripheral lymph nodes

increased B-1a cell number ( J:133215 )

• mice exhibit more CD19+B220^loCD5+CD43+CD23- B-1a cells in the spleen and peritoneal cavity compared to in wild-type mice

increased CD8-positive, alpha-beta T cell number ( J:133215 )

abnormal B cell morphology ( J:133215 )

• spleen and lymph node B cells exhibit increased cell size compared to in wild-type mice

abnormal CD4-positive, alpha beta T cell morphology ( J:133215 )

• CD4+ T cells exhibit increased proliferation and survival following stimulation with CD3 alone unlike wild-type cells

increased CD4-positive, alpha-beta T cell number ( J:133215 )

decreased spleen red pulp amount ( J:133215 )

intermingled spleen red and white pulp ( J:133215 )

abnormal spleen marginal zone morphology ( J:133215 )

• the spleen marginal zone is disrupted unlike in wild-type mice

decreased marginal zone B cell number ( J:133215 )

increased spleen white pulp amount ( J:133215 )

abnormal B cell activation ( J:133215 )

• B cells are more resistance than in wild-type mice to Fas-mediated cell death following activation

• activated B cells exhibit enhanced proliferation and survival compared to wild-type cells

increased B cell proliferation ( J:133215 )

• B-2 cell proliferation is enhanced following activation with anti-IgM or lipopolysaccharides unlike in wild-type cells

abnormal immunoglobulin level ( J:133215 )

increased IgG2a level ( J:133215 )

• 4- to 6-fold at 8 to 12 weeks of age

increased IgG2b level ( J:133215 )

• 4- to 6-fold at 8 to 12 weeks of age

increased IgG3 level ( J:133215 )

• 4- to 6-fold at 8 to 12 weeks of age

increased IgM level ( J:133215 )

• 4- to 6-fold at 8 to 12 weeks of age

abnormal CD4-positive, alpha-beta T cell physiology ( J:133215 )

• more CD4+ T cells produce IFN-gamma and IL-10 but not IL-4 or TNF than wild-type cells

• CD4+T cells from older mice produce more IFN-gamma and IL-10 than CD4+ T cells from younger mice

abnormal T cell activation ( J:133215 )

• activated T cells exhibit enhanced proliferation and survival compared to wild-type cells

growth/size/body

increased spleen weight ( J:133215 )

• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice

spleen hyperplasia ( J:133215 )

• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice

cellular

increased mesangial cell number ( J:133215 )

increased B cell proliferation ( J:133215 )

• B-2 cell proliferation is enhanced following activation with anti-IgM or lipopolysaccharides unlike in wild-type cells